



Supplementary Figure S1: Frequency of symptoms of psychosis at initial presentation of PDP (unweighted)




PD = Parkinson's disease

Supplementary Figure S2: Disruptiveness of symptoms of psychosis (unweighted)



Supplementary Figure S3: Frequency of comorbidities\* (unweighted)



\*Frequencies of comorbidities are based on data available in patient records at the time of the chart review and were not limited to the frequencies at diagnosis.

Supplementary Table S1: Reasons for change in intervention for PDP (weighted)

Country	Prior intervention requiring treatment change	Patient records (n)*	Lack of control of psychosis	Negative impact on motor function	Non-motor side effects	Other
France	PD medication adjustment	77	79%	24%	8%	1%
	Add quetiapine	3	0%	0%	100%	0%
	Add clozapine	12	80%	30%	13%	4%
	Add anti-dementia agent	19	83%	17%	0%	6%
Germany	PD medication adjustment	78	67%	32%	8%	4%
	Add quetiapine	25	48%	23%	28%	12%
	Add clozapine	6	22%	41%	19%	18%
	Add anti-dementia agent	14	56%	31%	10%	15%
Italy	PD medication adjustment	88	69%	42%	7%	2%
	Add quetiapine	22	82%	57%	7%	3%
	Add clozapine	14	57%	39%	18%	2%
	Add anti-dementia agent	28	82%	9%	5%	8%
Spain	PD medication adjustment	118	80%	10%	11%	1%
	Add quetiapine	37	41%	56%	0%	5%
	Add clozapine	9	15%	4%	82%	0%
	Add anti-dementia agent	44	51%	12%	38%	0%
UK	PD medication adjustment	88	68%	18%	25%	0%
	Add quetiapine	16	60%	9%	38%	0%
	Add clozapine	2	100%	0%	0%	0%
	Add anti-dementia agent	14	39%	2%	59%	0%
Overall	PD medication adjustment	449	73%	26%	11%	1%
	Add quetiapine	103	55%	43%	15%	5%
	Add clozapine	43	47%	20%	42%	2%
	Add anti-dementia agent	119	62%	12%	25%	4%

\* Sample sizes for select intervention categories in individual countries are limited. Totals add to over 100% due to selection of multiple reasons for change in treatment. PD = Parkinson's disease; PDP = Parkinson's disease psychosis.

Supplementary Table S2: Reasons for staying on current intervention for PDP (weighted)

Country	Current intervention	Patient records (n)*	Adequate control of psychosis	Referral to address psychosis	Waiting for response to treatment	Other
France	PD medication adjustment	55	69%	1%	31%	0%
	Add quetiapine	4	47%	0%	53%	0%
	Add clozapine	53	88%	4%	7%	2%
	Add anti-dementia agent	37	75%	0%	24%	3%
Germany	PD medication adjustment	86	75%	3%	25%	0%
	Add quetiapine	68	72%	0%	28%	5%
	Add clozapine	29	65%	0%	28%	9%
	Add anti-dementia agent	35	38%	0%	64%	1%
Italy	PD medication adjustment	61	63%	0%	42%	0%
	Add quetiapine	60	89%	3%	10%	0%
	Add clozapine	32	79%	0%	21%	0%
	Add anti-dementia agent	40	63%	0%	37%	0%
Spain	PD medication adjustment	72	81%	2%	14%	3%
	Add quetiapine	87	81%	2%	17%	0%
	Add clozapine	8	52%	0%	72%	0%
	Add anti-dementia agent	54	57%	8%	35%	0%
UK	PD medication adjustment	67	68%	3%	40%	0%
	Add quetiapine	49	63%	20%	48%	0%
	Add clozapine	7	51%	2%	47%	0%
	Add anti-dementia agent	46	51%	4%	47%	8%
Overall	PD medication adjustment	341	72%	2%	29%	1%
	Add quetiapine	268	77%	4%	24%	2%
	Add clozapine	129	77%	2%	21%	2%
	Add anti-dementia agent	212	59%	2%	40%	3%

\* Sample sizes for select intervention categories in individual countries are limited. Totals add to over 100% due to selection of multiple reasons for change in treatment. PD = Parkinson's disease; PDP = Parkinson's disease psychosis.